International Myeloma Society
23rd Annual MEETING & EXPOSITION
September 23-26, 2026 • Glasgow, Scotland

Daily Program Schedule

Wednesday, September 23, 2026

7:15-8:15 — **INDUSTRY SYMPOSIUM SUPPORTED BY GSK** C P D V — Hall 5

Evolving Horizons: Redefining outcomes in RRMM

Chair: Enrique Ocio

Introduction	Enrique Ocio
An unmet need persists in myeloma - the need for accessible BCMAs at first relapse	Joseph Mikhael
The challenge with rechallenge	Douglas Sborov
Patient Perspectives in Treatment Decision-Making	Jesus Berdeja
Clinical Decision-Making in Practice: Case-Based Discussion	All
Closing remarks	Enrique Ocio

8:15-9:15 — **OPENING CEREMONY** P D V — Hall 5

Welcome	
Tribute to Prof Robert A Kyle	
Pioneers in Myeloma	
President's Address	Philippe Moreau

9:15-10:00 — **KEYNOTE** C P D V — Hall 5

Co-chairs: Philippe Moreau and Gordon Cook

T cell engagers reorganise cytotoxic immunological synapses	Michael Dustin
Q&A	

10:00-11:20 — **NEWLY DIAGNOSED MULTIPLE MYELOMA** C P D V — Hall 5

Co-chairs: Philippe Moreau and Jesus San Miguel

Induction: Quadruplets for all NDMM patients?	Katja Weisel
What is the role today and in the near future of ASCT?	Aurore Perrot
Optimal maintenance approach	Charlotte Pawlyn

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

	Curative strategies for NDMM patients	Roberto Mina	
	Future directions and challenges	Philippe Moreau	
	Round table discussion	Ajai Chari, Wee Joo Chng, Caitlin Costello, Elena Zamagni	
11:30-12:00	**IMS/IMWG CONSENSUS UPDATE** C P D V		Hall 5
	Co-chairs: Vincent Rajkumar and Philippe Moreau		
	Defining cure in multiple myeloma: The IMS/IMWG consensus	Nikhil Munshi	
	Audience Q&A		
12:00-1:00	**LUNCH AND POSTER SESSION** P		Hall 4
12:00-12:50	**POSTER DISCUSSION** L P		Alsh
	Co-chairs: Masahiro Abe, Eileen Boyle, Hartmut Goldschmidt, Peter Voorhees		
	Updated safety and efficacy results for linvoseltamab (LINVO) in patients (pts) with high-risk smoldering multiple myeloma (HR-SMM): Phase 2 LINKER-SMM1 trial	Paula Rodriguez-Otero	
	Functional implications of FCRL5 mutations for cevostamab immune escape in multiple myeloma	Umair Munawar	
	Matching-adjusted indirect comparisons (MAICs) of efficacy and safety outcomes for anitocabtagene autoleucel versus ciltacabtagene autoleucel in 4L+ relapsed and/or refractory multiple myeloma (RRMM)	Surbhi Sidana	
	Prognostic Impact of [18F] FDG PET/CT Before and After BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Analysis	Luis-Esteban Tamariz-Amador	
	Second Primary Malignancies After Autologous Transplantation for Multiple Myeloma in the Modern Treatment Era: Incidence, Risk Factors, and Prognostic Impact Using a Competing-Risk Approach	Damian Mikulski	
	Efficacy and Safety of Daratumumab Plus VCd in Newly Diagnosed Amyloid Light-chain Amyloidosis with Cardiac Involvement: A Pooled Analysis of Asian Patients from AMY2009 and AMY3001	Jin Lu	
	POLB 001, an oral p38 MAPK inhibitor for the prevention of cytokine release syndrome	Liam Tremble	
	Proteogenomic Integration Reveals Predictive Signatures of Ibrutinib Response in Waldenström Macroglobulinemia	Christos Vlachos	
	Latent Effector T Cells Mediate Immunotherapy Responses in the Bone Marrow Microenvironment	Niklas Kehl	
	ALTITUDE - ALTernating Induction Therapies to achieve Undetectable Disease Endpoints: Ph 1/2 Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-Risk Newly Diagnosed Multiple Myeloma	Neha Korde	

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

12:00-12:50	**MEET THE EXPERTS** L P		
Boisdale	Frailty-adapted therapy	Ashley Rosko and Cyrille Touzeau	
Dochart	MRD-adapted therapy	Luciano Costa and Andrew Spencer	
Carron	Genomics and epigenetics	Ben Barwick and Francesco Maura	
1:00-2:30	**INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI** C P D V		Hall 5
	Redefining Patient-focused Care in NDMM: Advances in Methods of Administration		
	Chair: Robert Orlowski		
	Welcome and Introduction	Robert Orlowski	
	The NDMM Challenge: Unmet needs and treatment goals for patients	Claudio Cerchione	
	Transplant-ineligible NDMM: Tailoring treatment to meet all Ti patient profiles	Claudio Cerchione	
	Transplant-eligible NDMM: Optimizing induction and beyond	Stefan Knop	
	Advances in Administration Methods in MM: Hands-on demonstration	Stefan Knop	
	Patient Experience Discussion	Christine Skeet	
	Audience Q&A		
	Closing Remarks	Robert Orlowski	
2:30-3:30	**ABSTRACT SESSION 1** C P D		Hall 5
	Co-chairs: Melissa Alsina and Nizar Bahlis		
	Projecting Functional Cure in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in the MajesTEC-3 Study of Teclistamab-Daratumumab (Tec-Dara) Using a Mixture Cure Model	Niels van de Donk	
	Fifteen-Month Follow-Up from a Pivotal Trial of GR1803 in Patients with Relapsed/Refractory Multiple Myeloma	Jie Jin	
	Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Updated results from Part 1	Ja Min Byun	
	Cevostamab plus pomalidomide (pom) and dexamethasone (dex) induces durable remissions in BCMA-naïve patients with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm B extended follow-up data	Andrew Spencer	
	Evaluation of a vision-related anamnestic tool (VRAT) to guide Belantamab Mafodotin Dosing with Bortezomib and Dexamethasone for Multiple Myeloma: interim results from the UKMRA ProMMise D Trial	Rakesh Popat	

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

2:30-3:30	**ABSTRACT SESSION 2** C P D	Lomond Auditorium
	Co-chairs: Niccolo Bolli and Paola Neri	
	Refining Frailty Assessment in Transplant-Ineligible Multiple Myeloma: Geriatric Assessment in Hematology Enhances the Simplified Frailty Index for Benefit-Risk Evaluation of Quadruplet Therapy	Borja Puertas
	Hypogammaglobulinaemia (HG), infection risks and effects of immunoglobulin replacement therapy (IgG RT) in Multiple Myeloma (MM): A registry based longitudinal real-world-analysis (RWA)	Wolfgang Willenbacher
	Clinical Significance of Circulating Tumor Cells in Relapsed/ Refractory Multiple Myeloma	Daniel Bilek
	Poor outcomes post sequential BCMA and GPRC5D exposed myeloma can be improved by subsequent targeted agents versus conventional therapy: An IMWG Immunotherapy Registry Analysis	Murali Janakiram
	MRD depth by NGS and distinct clonotypic patterns below the limit of detection predict divergent relapse risk after sustained remission	Zachary Avigan
3:30-4:00	**NETWORKING BREAK**	Hall 4
4:00-5:20	**HOW TO TREAT FIRST RELAPSE?** C P D V	Hall 5
	Co-chairs: Sagar Lonial and Maria-Victoria Mateos	
	CAR-T	Krina Patel
	Combinations	Rakesh Popat
	ADC-based	Vania Hungria
	Limited access to new agents	Martin Kaiser
	Future directions and challenges	Maria-Victoria Mateos
	Round table discussion	Gordon Cook, Francesca Gay, Natalia Schutz, Keith Stewart

Thursday, September 24, 2026

7:15-8:15	**INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER** C P D V	Hall 5
	Redefining bispecific antibody care in myeloma: Expanding access through outpatient step-up dosing	
	Chair: C. Ola Landgren	
	Welcome and Introduction	C. Ola Landgren
	The Current RRMM Treatment Landscape	C. Ola Landgren
	Implementing Immunotherapies in the Outpatient Setting	Frances Seymour
	Coordinated Care, Confident Delivery: A Multidisciplinary Blueprint for Outpatient Bispecific Step-Up Dosing	Andrew Kowalski and Lindsay Hankey
	Expert Roundtable: Shaping the Future of Immunotherapy Delivery	All
	Q&A	All
	Closing remarks	C. Ola Landgren

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

8:30-9:50 **BLOOD-BASED TECHNOLOGY FOR DIAGNOSIS AND MONITORING** C P D V — Hall 5

Co-chairs: Shaji Kumar and Kenneth Anderson

Circulating tumor cells	Luca Bertamini
Mass spectrometry	Noemi Puig
Circulating tumor DNA	Suzanne Trudel
Immune markers of disease activity	Samir Parekh
Future directions and challenges	Shaji Kumar
Round table discussion	Ceri Bygrave, Jill Corre, Graham Jackson, P. Joy Ho

10:00-10:50 **AWARDS CEREMONY** P D V — Hall 5

Bart Barlogie Award: Sonja Zweegman

Ken Anderson Award: Nizar Bahlis

Waldenström Award: Sagar Lonial

11:00-12:00 **ABSTRACT SESSION 3** C P D — Hall 5

Co-chairs: Meral Beksac and Martin Kortüm

Double hit ultra-high risk myeloma treated with Isa-VRD plus cyclophosphamide induction and Isa-VRD consolidation: QoL analysis of the UKMRA RADAR trial in newly diagnosed transplant eligible patients	Karthik Ramasamy
Updated safety and efficacy of ramantamig (Ram; JNJ-5322) at the recommended phase 2 dose (RP2D), demonstrating feasibility of outpatient dosing (OPD) in relapsed/refractory multiple myeloma (RRMM)	Jeffrey Matous
DREAMM-9 Patient-Reported Vision-Related Function with Extended Belantamab Mafodotin Dosing Intervals with Bortezomib, Lenalidomide, Dexamethasone (BVRd) in Transplant Ineligible Multiple Myeloma	Hang Quach
A fixed-duration, modified cevostamab dosing regimen induces durable remissions that continue after completion in BCMA-naïve pts with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm A results	Amrita Krishnan
Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab (Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis	Luciano Costa

11:00-12:00 **ABSTRACT SESSION 4** C P D — Lomond Auditorium

Co-chairs: Lugui Qiu and Niels van de Donk

Augmenting TRAIL-dependent apoptosis enables BCMA CAR-T cells to overcome resistance in multiple myeloma	Mansour Poorebrahim
First-in-human phase Ia/Ib study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated safety and efficacy data	Jian Cui

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

	An AI-Designed BCMA/FcRL5 Targeting TriTE Overcomes Antigen Escape and Outperforms BCMA-Directed Therapy in Multiple Myeloma	Jessica Encinas Mayoral
	A CD4-Dominant, T-Helper-Skewed T Cell State Underlies Movement and Neurocognitive Toxicity After BCMA-Directed CAR-T Therapy in Multiple Myeloma	Theresia Akhlaghi
	Single-cell antigen:TCR mapping reveals tumor-specific effector T-cell responses in multiple myeloma	David Avigan
12:00-1:00	**LUNCH AND POSTER SESSION** (P)	Hall 4
12:00-12:50	**POSTER DISCUSSION** (L) (P)	Alsh
	Co-chairs: Jonathan Kaufman, Prashant Kapoor, Maria Theresa Krauth, Sonja Zweegman	
	Cure in Multiple Myeloma is Age-, Risk- and Treatment-Dependent: Long-Term Analyses from 6380 patients across UK Randomised Trials	David Cairns
	Circulating tumor cells and plasma MYD88 Mutation Allele Fraction as Prognostic Markers for Staging and Ibrutinib Response in Waldenström Macroglobulinemia	Tina Bagratuni
	Patient-Reported Outcomes (PROs) of Teclistamab-Based Treatment (tx) in Relapsed/Refractory Multiple Myeloma (RRMM) after 1-3 Lines of Therapy (LOT)	Katja Weisel
	Post-Infusion Immunophenotypic And Functional Characteristics Of Arlocabtagene Autoleucel (Arlo-Cel) In A First-In-Human (FiH), Phase 1 Trial In Relapsed/Refractory Multiple Myeloma (RRMM)	Susan Bal
	Neoantigen viral vector vaccination provides effective and durable tumor control in an aggressive Multiple Myeloma model	Marta Chesi
	Co-opting the BAFF-APRIL Pathway in Smouldering Myeloma (SMM) to Fuel Disease Progression	Elise Rees
	Complete-genome multiomics uncovers peri/centromeric rearrangements as hidden drivers of epigenomic rewiring in myeloma	Aneta Mikulasova
	The Role of Prehabilitation in Individuals Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma	Shannon Strader
	Dasatinib and Quercetin in Patients with Relapsed, Refractory Multiple Myeloma receiving CAR-T Therapy: First report from the Safety Run-in of the Phase II DART Trial	Christoph Schaefers
	Quantifying the Rise of Non-Cancer Mortality in Multiple Myeloma: A SEER Database Analysis (2000-2030)	Muhammad Talha Shaukat
12:00-12:50	**MEET THE EXPERTS** (L) (P)	
Boisdale	CAR-T in the outpatient setting	Adam Cohen and Murali Janakiram
Dochart	Bispecifics in the outpatient setting	Yael Cohen and Sham Mailankody
Carron	Evaluating immune system in MM	Madhav Dhodapkar and Bruno Paiva

(C) CME Accredited (L) Limited Space. First come, first served (P) In Person (D) On-Demand (V) Virtual (Live streamed)

1:00-2:30	**INDUSTRY SYMPOSIUM SUPPORTED BY JOHNSON & JOHNSON** C P D V ***The Red Thread in Multiple Myeloma: Moving Towards Cure*** *Chair: Sally Moore*		Hall 5
	Welcome	Sally Moore	
	Beginning the Red Thread towards cure in the frontline	Maria Gavriatopoulou, Sally Moore	
	Following the Red Thread towards cure in the second line	Maximilian Merz, Raphael Teipel, Selina Chavda, Sally Moore	
	Closing remarks	Sally Moore	
2:30-3:30	**IMS/AACR SESSION** C P D V *Co-chairs: Kenneth Anderson and Rafael Fonseca*		Hall 5
	CAR-T response rates - how to harness the microbiome?	Robert Jenq	
	Audience Q&A		
	Preclinical and clinical assessments: The impact of the gut microbiome on CAR T cells	Melody Smith	
	Audience Q&A		
3:30-4:00	**NETWORKING BREAK**		Hall 4
4:00-4:50	**SPECIAL SESSION: IMS/EHA** C P D V *Co-chairs: Maria-Victoria Mateos and Pieter Sonneveld*		Hall 5
	From gene profiles to therapeutic targets	Peter Valk	
	From hype to clinical wisdom: How to use AI without losing medicine	Adrian Mosquera	
	Audience Q&A		
5:00-6:00	**ABSTRACT SESSION 5** C P D *Co-chairs: Natalie Callander and Pankaj Malhotra*		Hall 5
	First-Year Results of Isatuximab-Iberdomide Maintenance in MRD-Positive Newly Diagnosed Multiple Myeloma Patients Included in the Phase 3 MIDAS Trial	Aurore Perrot	
	5-Year Sustained Minimal Residual Disease (MRD) Negativity and Survival with Daratumumab Maintenance (D-maint) in Transplant-Eligible (TE) NDMM: CASSIOPEIA Registry	Jill Corre	
	Discontinuation of maintenance therapy guided by minimal residual disease in newly diagnosed multiple myeloma: long-term results of the GEM2014MAIN study	David Moreno	
	Multi-Center Phase II Trial of Iberdomide and SQ Daratamumab as Post-ASCT Maintenance Therapy in Pts with Multiple Myeloma (the IBEX Trial): Initial Safety Analysis and Interim Efficacy Results.	Jeffrey Zonder	
	48-month survival analysis of the BENEFIT trial, isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients	Xavier Leleu	

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

5:00-6:00 **ABSTRACT SESSION 6** C P D — Lomond Auditorium

Co-chairs: Mariateresa Fulciniti and Niels Weinhold

Anticoagulation for ThrOmbosis prevention in Multiple Myeloma (ATOMM): thromboprophylaxis in elderly and renal impairment in a large UK real-world cohort	Marquita Camilleri
Myeloma Precursors Erode Durable Immunity Through Tumor Burden-Dependent Depletion of APRIL	Noe Perron
Mechanical loading of the bone during induction therapy improves bone regeneration in newly-diagnosed multiple myeloma patients (GMMG-HD8-INDEX trial)	Ulrike Dapunt
Plasma cfDNA Methylation Defines Progression-Associated Epigenetic States in Multiple Myeloma	Nour Alassi
Longitudinal liquid biopsy monitoring reveals distinct residual disease dynamics beyond bone marrow MRD assessment in newly diagnosed Multiple Myeloma	Carolina Terragna

Friday, September 25, 2026

7:15-8:15 **INDUSTRY SYMPOSIUM SUPPORTED BY GILEAD AND KITE ONCOLOGY** C P — Hall 5

Are we ready to say 'cure' in multiple myeloma

This symposium is not intended for healthcare professionals from the United Kingdom.

Chair: Jenny Ahlstrom

Welcome & introduction	Jenny Ahlstrom
A patient's perspective: What does 'cure' really mean?	Jenny Ahlstrom
Can we do better for our patients?	Rahul Banerjee
How close are we to a cure?	Fredrik Schjesvold
What strategy maximises the probability of a functional cure?	Rahul Banerjee and Gurbakhash Kaur
Audience Q&A: Bringing it all back to the patient	All
Conclusion & closing remarks	Jenny Ahlstrom

8:30-9:50 **MONITORING IMMUNE SYSTEM AND PREVENTING INFECTIONS AND ADVERSE EFFECTS** C P D V — Hall 5

Co-chairs: Nikhil Munshi and Noopur Raje

Immune fitness and immune reconstitution in myeloma	Yi Lin
Biomarkers to predict and monitor toxicities	Doris Hansen
Preventing infections in the era of CAR-T and Bispecific antibodies	Paula Rodriguez-Otero
Managing AEs without compromising efficacy	Surbhi Sidana
Future directions and challenges	Noopur Raje
Round table discussion	Adam Sperling, Thomas Martin, Mohamad Mohty, Karthik Ramasamy

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

10:00-10:50	**RINEY SESSION** C P D V	Hall 5
	Co-chairs: Nikhil Munshi, Kenneth Anderson, Suzanne Lentzsch	
	Targeting loss of the tumor suppressor TENT5C in multiple myeloma	Brian Walker
	Evaluating NKp30-Directed Bispecific NK Cell Engagers for Multiple Myeloma Therapy	Katja Klausz
	Precision Medicine Approaches to Overcoming IMiD Resistance in Multiple Myeloma	Vidyasagar Koduri
	Mutational processes of acquired resistance to bispecific T cell engagers in multiple myeloma	Holly Lee
11:00-12:00	**ABSTRACT SESSION 7** C P D	Hall 5
	Co-chairs: Xavier Leleu and Chandramouli Nagarajan	
	Teclistamab plus Talquetamab consolidation in newly diagnosed myeloma patients with positive measurable residual disease after DVRD induction : interim analysis of the phase 2 study IFM 2022-01	Cyrille Touzeau
	Phase 2 Study of Talquetamab (Tal), Daratumumab (D), and Lenalidomide (R) as Induction Therapy in Patients (pts) With Transplant Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM): MajesTEC-5	Leo Rasche
	A novel analytical approach to addressing the challenge of assessing overall survival in myeloma trials in the context of a rapidly evolving treatment landscape	Kara-Louise Royle
	Predicting Cure in Myeloma: Sustained MRD dynamics, genomic risk, and ISS define ultra-low-risk subgroup with favorable outcomes after stopping therapy	Zachary Avigan
	Feasibility of MRD-adapted Deferral of Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: Clinical and Translational Results from the Phase II MILESTONE Study	Susan Bal
11:00-12:00	**ABSTRACT SESSION 8** C P D	Lomond Auditorium
	Co-chairs: Irene Ghobrial and Jan Krönke	
	Investigation of the impact of peripheral neuropathic symptoms on quality of life in patients with smoldering multiple myeloma	Eileen Kurre
	Diffuse bone marrow activity in patients with smouldering Multiple Myeloma: a WB-MRI analysis	Gianluca Maiorana
	Long-term follow-up of the phase II EMN15/HOVON147 trial: carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with high-risk smoldering multiple myeloma	Dirk van Esser
	Clinically significant bone disease is uncommon in smouldering myeloma progressors monitored with modern imaging: findings from the prospective multi-centre UK MRA COSMOS study	Louise Ainley
	Predicting progression in smoldering multiple myeloma: a dynamic AI model that learns from each clinical visit	Anish Simhal
12:00-1:00	**LUNCH AND POSTER SESSION** P	Hall 4

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

12:00-12:50	**POSTER DISCUSSION** L P		Alsh
	Co-chairs: Meletios Dimopoulos, Lisa Leypoldt, Gareth Morgan, Alissa Visram		
	Longitudinal ctDNA Profiling Enables Early Detection of Relapse and Clonal Dynamics in Multiple Myeloma	Marina Martello	
	Evaluation of Patient-Reported Outcomes and Subgroup Analysis With Subcutaneous Isatuximab Delivered via On-Body Injector Compared With Intravenous Delivery From the Phase 3 IRAKLIA Trial	Fredrik Schjesvold	
	Treatment naïve GPRC5D negative multiple myeloma with t(11;14)	Juan-Jose Garces	
	Carfilzomib, Iberdomide, and Dexamethasone (KID) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from a Phase 1/2 Study	Noa Biran	
	Matching-Adjusted Indirect Comparisons (MAICs) of Anitocabtagene Autoleucel (anito-cel) versus Teclistamab and Talquetamab for the Treatment of 4L+ Relapsed and/or Refractory Multiple Myeloma (RRMM)	Krina Patel	
	Whole Proteome Analysis of Multiple Myeloma Patient Samples Provides New Insights into IMiD/CELMoD Resistance	Sarah Bird	
	Leveraging a high-fiber diet to intercept smoldering multiple myeloma progression and enhance early immunotherapy efficacy	Anna Policastro	
	First-in-Human Phase 1 Study of RD140, a Fully Human BCMA/GPRC5D Dual-Targeting FasT CAR-T, in Relapsed/Refractory Multiple Myeloma(RRMM) and Plasma Cell Leukemia(PCL)	Jin Lu	
	Characterization of the IKZF1 Interactome in Multiple Myeloma and Its Modulation by CELMoDs	Jing Fu	
	Clinical screening for Monoclonal Gammopathy - prevalence and outcomes	Sumeet Yadav	
12:00-12:50	**MEET THE EXPERTS** L P		
Boisdale	Choosing the optimal imaging test	Jens Hillengass and Efstathios Kastritis	
Dochart	Management of patients with extramedullary disease	Ajay Nooka and Paul Richardson	
Carron	Animal models	Marta Chesi and Karin Vanderkerken	
1:00 - 2:30	**INDUSTRY SYMPOSIUM PROVIDED BY PVI, PEERVIEW INSTITUTE FOR MEDICAL EDUCATION** C P D V		Hall 5
	Personalizing Multiple Myeloma Care: Evidence and Guideline-Informed Application of Current Treatment Options		
	Supported through an educational grant from Bristol Myers Squibb		
	Chair: Amrita Krishnan		
	Introduction: Modern Standards, Challenges, and Progress in MM	Amrita Krishnan	
	Seminar: Options for Early Myeloma Relapse With Current Therapeutics	Nisha Joseph	
	Workshop: Individualizing Care in Early Relapse Settings	Joshua Richter	
	Symposium Summary, Q&A, and Practical Takeaways	Amrita Krishnan	

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

2:30 - 3:00	**NETWORKING BREAK**	Hall 4

3:00-5:00	**PLENARY SESSION** C P D V	Hall 5
	Co-chairs: Faith Davies and Saad Usmani	
	Abstract Introduction	Saad Usmani
	CERVINO: A Randomized Phase 3 Study of Etentamig vs Investigator's Choice of Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Triple-Class Exposure	Peter Voorhees
	Abstract Introduction	Vincent Rajkumar
	Long-Term Outcomes with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) in the Phase 3 PERSEUS Study	Pieter Sonneveld
	Abstract Introduction	Marc Raab
	Iberdomide, Daratumumab, Dexamethasone (IberDd) Vs Daratumumab, Bortezomib, Dexamethasone (DVd) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From EXCALIBER-RRMM Phase 3 Study	Sagar Lonial
	Abstract Introduction	Noopur Raje
	First-in-Human In Vivo Generation of CD19/BCMA Dual-Targeting CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma	Jia Xu
	Abstract Introduction	Wee Joo Chng
	NSD2 Expression Remodels DNA Methylation, Creating a Targetable Epigenetic Dependency in t(4;14) Multiple Myeloma	Anna Baj
	Abstract Introduction	Faith Davies
	Re-defining ultra-high-risk myeloma by combining genomic and transcriptional risk assessment: an exploratory study of the UKMRA OPTIMUM/MUKnine trial	Sina Beer

5:00-6:00	**SPECIAL SESSION WITH PATIENT GROUPS** C P D V	Hall 5
	Co-chairs: Philippe Moreau and Rafat Abonour	
	MMRF	Hearn Cho
	IMF	Heather Cooper Ortner
	Myeloma UK	Sophie Castell
	Myeloma Patient Europe	Kate Morgan
	Myeloma Australia	Mark Henderson
	Round table discussion	

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

Saturday, September 26, 2026

7:15-8:15 — **INDUSTRY SYMPOSIUM SUPPORTED BY ABBVIE** (C P D V) — Hall 5

Leave No Cell Behind: The Quest for Cure in Multiple Myeloma

Chair: Adriana Rossi

Welcome and Introduction	Adriana Rossi
Achieving Deep Remission in Clinical Practice	Michel Delforge
Panel discussion and Q&A	All
Harnessing the Immune System	Meera Mohan
Panel discussion and Q&A	All
Long-term Disease Management & Functional Cure	Hans Lee
Panel discussion and Q&A	All

8:30-9:30 — **ABSTRACT SESSION 9** (C P D) — Hall 5

Co-chairs: Christine Chen and Wilson Gonsalves

The Benefit of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) on Depth and Durability of Response in the Phase 3 CEPHEUS Trial: Updated Minimal Residual Disease Analysis	Sonja Zweegman
IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients (pts) with relapsed or refractory multiple myeloma (R/R MM): results of a phase 1 study	Jing Li
BMS-986453, a Dual-targeting BCMA×GPRC5D Autologous CAR T cell Therapy in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results From a Phase 1 Trial	Doris Hansen
First-in-Human Clinical Proof-of-Concept of IASO206, an Intravenously Administered In Vivo BCMA CAR-T Therapy for Patients with Relapsed/Refractory Multiple Myeloma	Wenqiang Yan
Etentamig combined with pomalidomide plus dexamethasone (pom+dex) in relapsed/refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy: A Phase 1b dose-escalation and safety expansion study	Cesar Rodriguez

8:30-9:30 — **ABSTRACT SESSION 10** (C P D) — Lomond Auditorium

Co-chairs: Manoj Bhasin and Megan Weivoda

Epigenetic reactivation of ASS1 drives arginine metabolic adaptation in multiple myeloma	Linda Baughn
Immune Dysregulation in the Bone Marrow Following Autologous Stem Cell Transplant in Multiple Myeloma	Reyka Jayasinghe
Dynamic Changes in Plasma Cell and Immune Niches Underlie CAR-T Response in Multiple Myeloma	Li Ding
Recurrent Non-coding Mutational Hotspots Reveal Regulatory Drivers in Multiple Myeloma	Sreejeta Mondal
Single-Cell Analysis Reveals Stage-Specific γδ T-Cell Remodeling Across the Multiple Myeloma Continuum	Siddhartha Mantrala

9:30-10:20	**FUTURE TARGETS AND NEW MODALITIES OF THERAPY** P D V *Co-chairs: Sagar Lonial and Kwee Yong*		Hall 5
	AbbVie advances ABBV-2001/ISB 2001: A unique, single-molecule trispecific T-cell engager (TCE) approach toward robust anti-myeloma activity with superior tumor cytotoxicity	Saurabh Patel	
	BCMA x GPRC5D-Targeted CAR T-Cell Therapy: A Novel Approach in Relapsed/Refractory Multiple Myeloma	Shari Kaiser	
	BCMAb, a Monoclonal Antibody and Novel Modality for Targeting BCMA	Joanna Opalinska	
	Charting the path to cure with targeted combination immunotherapies	Mark Wildgust	
	The D-Domain BCMA CAR-T, Anitocabtagene Autoleucel (Anito-cel), Enables Deep Responses, Favorable Safety, and Efficient Manufacturing	Priyanka Nair-Gupta	
	Bispecifics and Beyond: Future Therapies with Potential to Change the Lives of Patients with Multiple Myeloma	Samhita Chakraborty	
	Early intervention in multiple myeloma precursor conditions using BCMA×CD3 bispecific antibody therapy to prevent progression to multiple myeloma and improve patient outcomes	Shawn Sarkaria	
	Sanofi's approach to Multiple Myeloma: Evaluating alternative mechanisms and combinations in an evolving landscape	Corina Oprea	
	Cevostamab, a FcRH5xCD3 bispecific T- cell engager for the treatment of Multiple Myeloma	Paresh Sewpaul	
10:30-11:00	**NETWORKING BREAK**		Hall 5
11:00-12:00	**ABSTRACT SESSION 11** C P D *Co-chairs: Craig Cole and Hang Quach*		Hall 5
	BCMA CAR T-Cell Therapy (Equecabtagene Autoleucel, Eque-cel) for Multiple Myeloma in Chinese Clinical Practice: A Large Real-World evidence of 281 Patients	Jin Lu	
	Outcomes of anti-BCMA CAR-T-cell therapy in patients with relapsed/refractory multiple myeloma and CNS involvement based on a multicenter real-world study with extended follow-up	Sven Neubert	
	Phase II trial of fixed-duration consolidation with elranatamab post-idecabtagene vicleucel CAR-T (EPIC) to deepen responses and MRD-negativity in relapsed or refractory multiple myeloma	Benjamin Puliafito	
	Mitigating Cilta-cel-Associated Delayed Neurotoxicity in Patients with High Lymphocyte Expansion: A Prospective Observational Comparative Study of Prophylactic Cyclophosphamide	Christoph Schaefers	
	MRD-Guided Frontline T-Cell Redirection therapy for Newly Diagnosed High-Risk Multiple Myeloma using Teclistamab-Daratumumab Intensification and Talquetamab-Daratumumab Early Rescue intervention	Paula Rodríguez-Otero	

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

11:00-12:00	**ABSTRACT SESSION 12** C P D *Co-chairs: Mehmet Samur and Holly Lee*	Lomond Auditorium
	Multi-omic characterization of Teclistamab resistance reveals diverse evolutionary trajectories in RRMM: results from the RESISTEC trial	Tom Lesluyes
	Targeting a new metabolic-epigenetic axis towards improved CAR T therapy in Multiple Myeloma	Urvi Shah
	Dysregulated RAS signaling modulates apoptotic dependencies and therapeutic response in multiple myeloma	Rebecca Owens
	Persistent Mucosal CAR-T Cells and Interferon-Driven Inflammation Drive BCMA-Targeted CAR-T Therapy-Associated Enterocolitis	Adolfo Aleman
	Distinct immune and genomic signatures predict resistance to ibrutinib therapy in Waldenström macroglobulinemia	Tina Bagratuni
12:00-12:50	**DEBATE** C P D V *Co-chairs: Sonja Zweegman and Vincent Rajkumar*	Hall 5
	CAR-T	Simon Harrison
	TCE	Andrew Yee
	ADC	Evangelos Terpos
1:00-2:00	**ABSTRACT SESSION 13** C P D *Co-chairs: Noa Biran and Salomon Manier*	Hall 5
	Low-Dose BCMA×CD3 Bispecific Antibody CM336 Induces Rapid and Universal Deep Hematologic Responses in Newly Diagnosed Systemic AL Amyloidosis: Primary Analysis of the Prospective Phase 2 AL-003 Trial	Jieqiong zhou
	Dara-VRD Plus Tandem Autologous Stem Cell Transplantation Followed by Prolonged Consolidation for Primary Plasma Cell Leukemia: A French Phase II Prospective Trial	Alexis Talbot
	Self Administration of Bortezomib in Multiple Myeloma and Amyloidosis: A Prospective Feasibility Study	Aditya Nair
	Racial and Socioeconomic Drivers of Second Primary Malignancies in Multiple Myeloma: A Machine Learning Analysis	Muhammad Talha Shaukat
	Interim report of phase I results of a phase I/II, open label study to evaluate safety, tolerability, and efficacy of elranatamab in patients with relapsed AL amyloidosis	Giada Bianchi
1:00-2:00	**ABSTRACT SESSION 14** C P D *Co-chairs: Leo Rasche and Mala Shanmugam*	Lomond Auditorium
	Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): an update from DREAMM-8	Meletios Dimopoulos
	NKp30 is Expressed on Natural Killer (NK) Cells of Multiple Myeloma Patients and Can be Potently Activated by [GPRC5DxNKp30] and [CD38xNKp30] Bispecific NK Cell Engagers	Katja Klausz

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

	Iberdomide priming enhances anti-BCMA CAR-T efficacy in Multiple Myeloma	Adolfo Aleman	
	Clinical translation of LV169, a CD3-targeted lentiviral vector for in vivo delivery of a BCMA-CAR transgene to T cells in patients with multiple myeloma	Yi Lin	
	Rapid Renal & Hematologic Responses and Favorable Safety with IsaVCd Induction & IsaR Maintenance in NDMM Patients with Severe Renal Impairment: Phase 2 Study Final Results-Greek Myeloma Study Group	Evangelos Terpos	
2:00-3:00	**HIGHLIGHTS OF THE 2026 ANNUAL MEETING** C P D V *Co-chairs: Leif Bergsagel and Hermann Einsele*		Hall 5
	Basic Science	Lawrence Boise	
	Translational	Marc Raab	
	Clinical	Hira Mian	
3:00-3:15	**CLOSING CEREMONY** P D V		Hall 5

C CME Accredited L Limited Space. First come, first served P In Person D On-Demand V Virtual (Live streamed)

The IMS gratefully acknowledges the following organizations for their sponsorship of the 23rd IMS Annual Meeting:

TITANIUM LEVEL

Bristol Myers Squibb®

Johnson&Johnson

sanofi

PLATINUM LEVEL

abbvie

GILEAD | Kite

GSK

Pfizer Oncology

SILVER LEVEL

REGENERON
SCIENCE TO MEDICINE®

BRONZE LEVEL

AstraZeneca

Roche